Holen Sie sich die Stockscreener-App
80.14
2.73%
-2.25
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Form 4 Mirum Pharmaceuticals Inc: Robert Paul Myers (Chief Medical Officer) For: 9 October By Investing.com - Investing.com South Africa
Medical chief receives 40,000 options and a 25,000-share stock grant at Mirum Pharmaceuticals (MIRM). - Stock Titan
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
Mirum Pharmaceuticals, Inc.common stock (Nasdaq:MIRM) Stock Quote - FinancialContent
Form 4 Mirum Pharmaceuticals Inc For: 6 October By Investing.com - Investing.com Nigeria
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - stocktitan.net
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - stocktitan.net
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com UK
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - Investing.com
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Canada
Mirum CEO Christopher Peetz sells $2.96 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - stocktitan.net
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - stocktitan.net
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - stocktitan.net
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing - Yahoo Finance
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
0.03%
3.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):